Symbols

EXEL

Exelixis·NASDAQ

--(--)

EXEL fundamentals

EXEL Q4 2025 Earnings

Exelixis (EXEL) released its earnings on Feb 10, 2026: revenue was 598.66M (YoY +5.63%), beat estimates; EPS was 0.94 (YoY +95.83%), beat estimates.

Revenue / YoY

598.66M

+5.63%

EPS / YoY

0.94

+95.83%

Report date

Feb 10, 2026

EXEL Earnings Call Summary for Q4,2025

Revenue Growth: U.S. cabo franchise up 17% to $2.12B in 2025, driven by NET expansion and RCC leadership.
Zanza Milestone: Zanzalintinib NDA accepted for CRC, targeting December 2026 PDUFA date.
Commercial Expansion: GI sales team doubled to capitalize on NET growth and zanza launch readiness.
Pipeline Momentum: 7 zanza trials underway, including MRD+ CRC and non-clear cell RCC studies.
Financial Strength: $1.66B cash, $590M remaining under $750M share repurchase program.
Strategic Focus: Build multi-franchise oncology business in solid tumors with product, indication, and modality leadership.

Earnings

EPS

Revenue

Revenue & Expenses

EXEL has released its 2025 Q4 earnings report, with revenue of 598.66M, reflecting a YoY change of 5.63%, and net profit of 244.53M, showing a YoY change of 74.84%. The Sankey diagram below clearly presents EXEL's revenue sources and cost distribution.

Key Indicators

Exelixis (EXEL) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Exelixis (EXEL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Exelixis (EXEL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Exelixis (EXEL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown